<?xml version="1.0" encoding="UTF-8"?>
<p id="p0045">Within months of publication of the SARS-CoV-2 genome sequence, work began on dozens of vaccine candidates (
 <ext-link ext-link-type="uri" xlink:href="https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1" id="intref0030" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1</ext-link>), enabled by insights from the SARS-CoV and MERS-CoV vaccine development and well-characterized vaccine antigen expression platforms, including those shown to be safe in humans. Several vaccines, described below, have entered phase 1 clinical trials to evaluate safety in small numbers of subjects (
 <xref rid="tbl1" ref-type="table">Table 1</xref> ). However, given the lack of established and tractable pre-clinical disease models of SARS-CoV-2 pathogenesis, these vaccines have advanced to human trials without data in animals establishing efficacy against COVID-19.
</p>
